Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma

被引:14
作者
Nocera, Luigi [1 ,2 ]
Stolzenbach, Lara F. [1 ,3 ]
Ruvolo, Claudia Colla [1 ,4 ]
Wenzel, Mike [1 ,5 ]
Tian, Zhe [1 ]
Rosiello, Giuseppe [2 ]
Bravi, Carlo A. [2 ]
Candela, Luigi [2 ]
Basile, Giuseppe [2 ]
Larcher, Alessandro [2 ]
Shariat, Shahrokh F. [6 ,7 ,8 ,9 ,10 ,11 ]
Bertini, Roberto [2 ]
Capitanio, Umberto [2 ]
Salonia, Andrea [2 ]
Montorsi, Francesco [2 ]
Briganti, Alberto [2 ]
Karakiewicz, Pierre I. [1 ]
机构
[1] Univ Montreal, Ctr Hlth, Div Urol, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[2] IRCCS San Raffaele Sci Inst, Urol Res Inst, Div Expt Oncol, Unit Urol, Milan, Italy
[3] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[4] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Naples, Italy
[5] Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[6] Med Univ Vienna, Dept Urol, Ctr Comprehens Canc, Vienna, Austria
[7] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[8] Univ Texas Southwestern, Dept Urol, Dallas, TX USA
[9] Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic
[10] IM Sechenov First Moscow State Med Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[11] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan
来源
EJSO | 2021年 / 47卷 / 05期
关键词
Kidney cancer; KCa; Surgical treatment; Nephrectomy; Surgery; COVID; ROBOTIC PARTIAL NEPHRECTOMY; CLINICAL T1; OUTCOMES; DISEASE;
D O I
10.1016/j.ejso.2020.10.040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We hypothesized that pT3a stage at nephrectomy can be accurately predicted in cT1N0M0 clear cell-renal cell carcinoma (cc-RCC) patients. Of 236 patients, treated with either partial or radical nephrectomy (2005-2019), 25 (10.6%) harbored pT3a stage. Multivariable logistic regression models predicting pT3a were fitted using age, tumor size, tumor location and exophytic rate. The new model was 81% accurate. In calibration plots, minimal departures from ideal prediction were recorded. In decision curve analyses, a net-benefit throughout all threshold probabilities was recorded relative to the treat-all or treat-none strategies. Using a probability cut-off of 21% for presence of pT3a stage, 38 patients (16.1%) were identified, in whom pT3a rate was 36.8%. Conversely, in 198 patients (83.9%) below that cut-off, the rate of pT3a was 5.6%. Alternative user-defined cut-offs may be selected. The new model more accurately identifies a subgroup of cT1N0M0 cc-RCC patients with substantially higher risk of pT3a stage than average. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1187 / 1190
页数:4
相关论文
共 15 条
  • [1] Renal Mass and Localized Renal Cancer: AUA Guideline
    Campbell, Steven
    Uzzo, Robert G.
    Allaf, Mohamad E.
    Bass, Eric B.
    Cadeddu, Jeffrey A.
    Chang, Anthony
    Clark, Peter E.
    Davis, Brian J.
    Derweesh, Ithaar H.
    Giambarresi, Leo
    Gervais, Debra A.
    Hu, Susie L.
    Lane, Brian R.
    Leibovich, Bradley C.
    Pierorazio, Philip M.
    [J]. JOURNAL OF UROLOGY, 2017, 198 (03) : 520 - 529
  • [2] Renal cancer
    Capitanio, Umberto
    Montorsi, Francesco
    [J]. LANCET, 2016, 387 (10021) : 894 - 906
  • [3] Impact of pathological T3a upstaging on oncological outcomes of clinical T1 renal cell carcinoma: a meta-analysis
    Chen, Luyao
    Deng, Wen
    Liu, Xiaoqiang
    Wang, Gongxian
    Fu, Bin
    [J]. JOURNAL OF CANCER, 2019, 10 (20): : 4998 - 5006
  • [4] FUKUI S, 2019, DIAGNOSTICS, V9
  • [5] Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004-2013
    Ghanie, Amanda
    Formica, Margaret K.
    Wang, Dongliang
    Bratslavsky, Gennady
    Stewart, Telisa
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (02) : 237 - 245
  • [6] Outcomes and Predictors of Clinical T1 to Pathological T3a Tumor Up-Staging after Robotic Partial Nephrectomy: A Multi- Institutional Analysis
    Gorin, Michael A.
    Ball, Mark W.
    Pierorazio, Phillip M.
    Tanagho, Youssef S.
    Bhayani, Sam B.
    Kaouk, Jihad H.
    Rogers, Craig G.
    Stifelman, Michael D.
    Khalifeh, Ali
    Kumar, Ramesh
    Sivarajan, Ganesh
    Allaf, Mohamad E.
    [J]. JOURNAL OF UROLOGY, 2013, 190 (05) : 1907 - 1911
  • [7] Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria
    Hamilton, Zachary A.
    Capitanio, Umberto
    Pruthi, Deepak
    Ghali, Fady
    Larcher, Alessandro
    Patel, Devin N.
    Eldefrawy, Ahmed
    Patel, Sunil
    Cotta, Brittney H.
    Bradshaw, Aaron W.
    Meagher, Margaret F.
    Miller, Nathan S.
    Carenzi, Cristina
    Wan, Fang
    Liss, Michael A.
    McGregor, Thomas
    Montorsi, Francesco
    Derweesh, Ithaar H.
    [J]. UROLOGY, 2020, 138 : 60 - 68
  • [8] Jeong SH, 2016, PLOSE ONE, V11
  • [9] Katz EC, 2020, J UROL, DOI DOI 10.1010/971110000000000001034
  • [10] EAU Guidelines on Renal Cell Carcinoma: 2014 Update
    Ljungberg, Borje
    Bensalah, Karim
    Canfield, Steven
    Dabestani, Saeed
    Hofmann, Fabian
    Hora, Milan
    Kuczyk, Markus A.
    Lam, Thomas
    Marconi, Lorenzo
    Merseburger, Axel S.
    Mulders, Peter
    Powles, Thomas
    Staehler, Michael
    Volpe, Alessandro
    Bex, Axel
    [J]. EUROPEAN UROLOGY, 2015, 67 (05) : 913 - 924